Máj- és epeúti rák: vizsgálatok itt: Kína
616 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 1/2. fázisNot yet taking people in KínaA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Where
- Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nanyang, Shanghai, Xi'an
- Életkor
- 18 év and over
- People
- 198 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00 - 2. fázisNot yet taking people in KínaChidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 41
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07890506 - 1/2. fázisTaking peopleA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Where
- Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
- Életkor
- 18 év and over
- People
- 862 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05914116 - 1. fázisTaking peopleA First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
- Where
- Fujian, Wuhan, Xuhui
- Életkor
- 18 év and over
- People
- 148 worldwide
- Run by
- Bayer
See details and how to joinNCT06764316 · EU 2024-516615-25-00 - 1/2. fázisTaking people68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 100
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07590336 - 2. fázisNot yet taking people in KínaSBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 33
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT07882056 - 1/2. fázisTaking peopleAVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Where
- Beijing, Changsha, Chongqing, Harbin, Jinan, Nanchang, Shenyang, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 480 worldwide
- Run by
- Avenzo Therapeutics, Inc.
See details and how to joinNCT07038343 - 2. fázisTaking peoplePhase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 38
- Run by
- Jinbo Yue
See details and how to joinNCT07030140 - 2. fázisTaking peopleBITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
- Where
- Jinan
- Életkor
- 18 év to 70 év
- People
- 54
- Run by
- Shandong Cancer Hospital and Institute
See details and how to joinNCT07062055 - 2. fázisTaking peoplePolymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer
- Where
- Beijing
- Életkor
- 18 év to 74 év
- People
- 25
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07159204 - No phaseTaking people68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 50
- Run by
- Peking University Third Hospital
See details and how to joinNCT07760012 - 1/2. fázisTaking peopleFirst in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Where
- Chengdu, Guangzhou, Harbin, Shanghai
- Életkor
- 18 év and over
- People
- 304 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06795022 · EU 2024-516698-56-00 - 3. fázisTaking peoplePhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Where
- Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shenzhen, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év to 99 év
- People
- 620 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00 - 3. fázisTaking peopleContinuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 132
- Run by
- Shandong Cancer Hospital and Institute
See details and how to joinNCT06841172 - 3. fázisTaking peoplePhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Where
- Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou, Guangzhou, Guiyang, Harbin, Hefei, Hohhot, Kunming, Linyi, Lishui, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Neijiang, Shandong, Shanghai, Shenyang, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 1220 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00 - 1. fázisTaking peoplePD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
- Where
- Chengdu
- Életkor
- 18 év to 70 év
- People
- 9
- Run by
- West China Hospital
See details and how to joinNCT07053072 - 2. fázisNot yet taking people in KínaLenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
- Where
- Guangzhou
- Életkor
- 18 év to 80 év
- People
- 100
- Run by
- Sun Yat-sen University
See details and how to joinNCT07870772 - 2/3. fázisTaking peopleHepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
- Where
- Nanning
- Életkor
- 18 év to 75 év
- People
- 62
- Run by
- Guangxi Medical University
See details and how to joinNCT05062837 - 1/2. fázisTaking peopleSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 138 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227012 · EU 2025-523525-17-00 - 2. fázisNot yet taking people in KínaFecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07847671 - No phaseNot yet taking people in KínaSurgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- Where
- Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
- Életkor
- 18 év to 80 év
- People
- 60
- Run by
- West China Hospital
See details and how to joinNCT07866612 - No phaseTaking peopleAdjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
- Where
- Nanning
- Életkor
- 18 év to 75 év
- People
- 10 000
- Run by
- Guangxi Medical University
See details and how to joinNCT05221398 - 1. fázisNot yet taking people in KínaPhase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
- Where
- Nanjing, Shanghai
- Életkor
- 18 év to 75 év
- People
- 70
- Run by
- Acepodia Biotech, Inc.
See details and how to joinNCT07861425 - 2. fázisTaking peopleA Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 38
- Run by
- Haitao Zhao, MD
See details and how to joinNCT07850791 - No phaseTaking peopleSurgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
- Where
- Chengdu
- Életkor
- 18 év to 80 év
- People
- 100
- Run by
- West China Hospital
See details and how to joinNCT07410715